Acadia Pharmaceuticals stock
ACADNASDAQAcadia Pharmaceuticals Inc., HealthcareISIN US0042251084
62Score 62 out of 100, Neutral
Price and trend
32 / 100
Price history
−23% in one yearThe chart shows daily closes over 20 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Below the 200-day line: the price is 22% below it.
Since November 2026 the 50-day line has been below the 200-day line; the trend has turned down.
Normal: the price is neither overheated nor sold off (RSI 40).
The price is 40% below its 52-week high. Largest decline in 20 years: 96% (August 2007 to November 2010).
Chart figures for advanced users
- SMA 50$22.18
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$23.41
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)40
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDbelow the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$16.50
- The lowest closing price of the last twelve months.
- Resistance$30.57
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Acadia Pharmaceuticals Inc. belongs to the Biotechnology industry (United States) and, with a market value of $3.17B, is number 100 of 296 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $1.07B (up 11.9% year on year) and earnings of $391M (up 72.7%).
- For fiscal 2026, analysts expect on average revenue of $1.27B (up 18.9%) and adjusted earnings per share of $0.68 (down 70.2%).
Show more
- MEQIRI Score 62 out of 100 (Neutral): rank 242 of 714 in Healthcare, median 53.
- The P/E is 8.9 (Biotechnology median 21.3, own median of recent years 12.5).
- Our model puts fair value at $39.34, with the price 53% below it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- High return on capitalReturn on invested capital 42.9% in fiscal 2025, Biotechnology median −24.3%.Profitability 97
- Modestly valuedP/E 8.9, Biotechnology median 21.3, own median 12.5.Valuation 92
- Below fair valuePrice 53% below the fair value of $39.34.Valuation 92
Weaknesses
- Volatile share priceVolatility 46% a year over the last 12 months.
Its standout strengths are profitability and valuation, while technical analysis and momentum hold the score back.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
Fundamental quality fluctuates.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk high
How well MEQIRI warnsOne of the 30% with the highest crash risk among smaller stocks.
From 2016 to 2025, 36 in 100 such stocks fell 30% or more within a year, against a group average of 23 in 100.
What drives the risk
- weak fundamentals
- price far below its 52-week high
- high price swings
Valuation
Valuation signal
Significantly undervaluedIn our model the price counts as cheap below $28.10 and expensive above $65.57 (uncertainty high, based on the price swings of the past year).
The two parts of the fair value come to $34.73 (cash-flow model) and $43.95 (industry comparison), and the gap between them shows how uncertain the estimate is. The price is below both.
Calculated with a cost of equity of 9.3%. At 10.3% the fair value would be $36.42, at 8.3% it would be $43.58.
Valuation metrics
Half from the cash-flow model, half from earnings times the industry P/E (21.3).
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue rose 14.8% on the twelve months before. Revenue has grown strongly since 2006, at around 29% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 92%, operating 10%, net 36%. Last 12 months: net 30%.
Debt & balance sheet
latest quarterThe balance sheet is solid, with low debt and comfortable interest coverage.
Earnings
- Next earnings
- 24 Feb 2027in 104 days
- Last reported
- 4 Nov 2026EPS reported $0.31 (expected $0.20)above expectations
Analyst estimates
Analysts have raised their 2026 earnings estimate by 11.1% since 15 Oct 2026.
- Earnings per share
- $0.68+11.1%
- Revenue
- $1.27B+0.2%
- Earnings per share
- $0.99+6.3%
- Revenue
- $1.44B+0.1%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook raised
Share price after the results: +12.5%Daybue net sales guidance raised to $480 to $510 million (before: $460 to $490 million), total revenue $1.24 to $1.3 billion, with lower R&D spending.
“We're raising our DAYBUE net sales outlook to $480 million to $510 million, up from $460 million to $490 million.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 4 Aug 2026 (fiscal Q2 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases in the last 6 months. 3 insiders sold, $1.5M in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
- Schneyer Mark C.Sale
30 Oct 2026, EVP, CHIEF FINANCIAL OFFICER
- Shares
- 3,321
- Price
- $20.88
- Value
- $69,342
- Schneyer Mark C.Sale
6 Aug 2026, EVP, CHIEF FINANCIAL OFFICER
- Shares
- 14,292
- Price
- $29.22
- Value
- $417,604
- Schneyer Mark C.Sale
5 Aug 2026, EVP, CHIEF FINANCIAL OFFICER
- Shares
- 5,849
- Price
- $29.00
- Value
- $169,638
Show 3 more
Partial trades from one filing are shown in one row, with the average price.
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Acadia Pharmaceuticals
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
714 rated companies in Healthcare
- This company
- 62
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Biotechnology
The next larger and next smaller companies by market value
- CelcuityCELC $3.55B28
- Dyne TherapeuticsDYN $3.37B36
- Disc MedicineIRON $3.34B42
- Telix PharmaceuticalsTLX $3.23B40
- IDEAYA BiosciencesIDYA $3.16B39
- VericelVCEL $3.03B66
- Xeris Biopharma HoldingsXERS $3.02B56
- XencorXNCR $3B46
ETFs that hold Acadia Pharmaceuticals
Held by 16 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| iShares Healthcare Innovation UCITS ETF2B78 | 0.26% | 0.40% | €1.49B |
| iShares Nasdaq US Biotechnology UCITS ETF2B70 | 0.24% | 0.35% | €1.21B |
| iShares Ageing Population UCITS ETF2B77 | 0.23% | 0.40% | €807M |
Show 5 more
| iShares S&P SmallCap 600 UCITS ETFIUS3 | 0.15% | 0.30% | €2.28B |
| L&G Russell 2000 US Small Cap Quality UCITS ETFETLZ | 0.12% | 0.30% | €185.82M |
| State Street SPDR Russell 2000 U.S. Small Cap UCITS ETF (Acc)ZPRR | 0.08% | 0.30% | €4.22B |
| Xtrackers Russell 2000 UCITS ETF 1CXRS2 | 0.07% | 0.30% | €2.17B |
| State Street SPDR MSCI USA Small Cap Value Weighted UCITS ETFZPRV | 0.02% | 0.30% | €944.34M |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 11 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 18 Sep 2026)
- Valuation signal Undervalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.